CompletedInterventionalPhase 1Last updated Jul 29, 2009

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Regimen, Parallel-Group Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGG-523 Administered Orally to Subjects With Severe Osteoarthritis

Overview

ClinicalTrials.gov ID: NCT00454298
Lead Sponsor: Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY
Brief Summary: The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or twice a day for 4 weeks.
Study Type

Status

Overall Status: Completed
Start Date: May 2007
Primary Completion Date: Mar 2008Actual
Completion Date: Mar 2008Actual

Study Record Dates

First Submitted: Mar 29, 2007
First Submitted that Met QC Criteria: Mar 29, 2007
First Posted: Mar 30, 2007Estimated
Last Update Submitted that Met QC Criteria: Jul 28, 2009
Last Update Posted: Jul 29, 2009Estimated
Last Verified: Jul 2009

NCT00427687Completed

Study Evaluating AGG-523 in Subjects With Osteoarthritis

NCT00380900Completed

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

NCT00944892Completed

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

NCT03311009Completed

A Study With GLPG1972 in Osteoarthritis Subjects

NCT01239017Withdrawn

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

NCT03595618Completed

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis